BiotechTube

Gelsemium Sempervirens + Gelsemium Sempervirens + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anxiety

Conditions

Anxiety

Trial Timeline

Jun 1, 2009 → May 1, 2010

NCT ID
NCT00914329

About Gelsemium Sempervirens + Gelsemium Sempervirens + Placebo

Gelsemium Sempervirens + Gelsemium Sempervirens + Placebo is a phase 3 stage product being developed by Boiron for Anxiety. The current trial status is completed. This product is registered under clinical trial identifier NCT00914329. Target conditions include Anxiety.

What happened to similar drugs?

19 of 20 similar drugs in Anxiety were approved

Approved (19) Terminated (2) Active (1)
✅Duloxetine + PlaceboEli LillyApproved
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
✅Cariprazine + PlaceboAbbVieApproved
✅EscitalopramAbbVieApproved
✅QuetiapineAstraZenecaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅QuetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00914329Phase 3Completed

Competing Products

20 competing products in Anxiety

See all competitors
ProductCompanyStageHype Score
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
Duloxetine Hydrochloride + placeboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
43
risperidone oral tabletsJohnson & JohnsonPhase 3
40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
27
ABBV-932 + PlaceboAbbViePhase 1
29
Cariprazine + PlaceboAbbVieApproved
43
EscitalopramAbbVieApproved
43
QuetiapineAstraZenecaApproved
43
Quetiapine extended release tablet + PlaceboAstraZenecaApproved
43
AZD7325 + Radioligand (11C) flumazenilAstraZenecaPhase 1
29